electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

electroCore (NASDAQ: ECOR), a bioelectronic medicine and wellness company, has appointed Andy Brown as VP, Corporate Controller effective September 9, 2025. As part of his employment package, Brown was granted 10,000 restricted stock units (RSUs) as an inducement award under NASDAQ Listing Rule 5635(c)(4).

The RSUs will vest in three equal installments of 33% each on the first, second, and third anniversaries of the grant date, contingent upon Brown's continued employment. Upon vesting, the RSUs will be converted into shares of electroCore's common stock.

[]

News Market Reaction

+2.24%

1 alert

+2.24% News Effect

On the day this news was published, ECOR gained 2.24%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

ROCKAWAY, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Andy Brown has joined electroCore, effective September 9, 2025, as the Company’s VP, Corporate Controller. The Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Mr. Brown in connection with the commencement of his employment. The RSUs were granted as an inducement material to Mr. Brown’s commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). 33% of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Mr. Brown’s continued employment by the Company on the applicable vesting date. Upon vesting, the RSUs shall be settled in shares of the Company’s common stock.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance. For more information, visit www.electrocore.com.

Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com

FAQ

Who is the new VP, Corporate Controller at electroCore (NASDAQ: ECOR)?

Andy Brown was appointed as electroCore's VP, Corporate Controller, effective September 9, 2025.

What compensation package did electroCore (ECOR) offer to Andy Brown?

Andy Brown received an inducement grant of 10,000 restricted stock units (RSUs) that vest over three years, with 33% vesting annually.

How will the RSUs vest for electroCore's new Corporate Controller?

The RSUs will vest in three equal installments of 33% on the first, second, and third anniversaries of the grant date, subject to continued employment.

What is electroCore's (ECOR) main business focus?

electroCore is a commercial-stage bioelectronic medicine and wellness company listed on NASDAQ.